# Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)

> **NCT06353087** · — · RECRUITING · sponsor: **Pfizer** · enrollment: 200 (estimated)

## Conditions studied

- Dermatitis, Atopic
- Dermatitis
- Eczema
- Skin Diseases
- Immune System Diseases
- Janus Kinase Inhibitors

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06353087
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2026-05-15
- **Final completion:** 2026-05-15
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06353087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06353087, "Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06353087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*